

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3056344

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ISIS PHARMACEUTICALS, INC.	11/08/2007
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	REGULUS THERAPEUTICS, LLC
<b>Street Address:</b>	1896 RUTHERFORD ROAD
<b>City:</b>	CARLSBAD
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92008
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14143943
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(608)662-1276
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	macheckett@casimirjones.com
<b>Correspondent Name:</b>	REBECCA B. SCARR
<b>Address Line 1:</b>	CASIMIR JONES S.C.
<b>Address Line 2:</b>	2275 DEMING WAY, STE 310
<b>Address Line 4:</b>	MIDDLETON, WISCONSIN 53562
<b>ATTORNEY DOCKET NUMBER:</b>	REGUL-32413/US-20/DIV
<b>NAME OF SUBMITTER:</b>	REBECCA B. SCARR
<b>SIGNATURE:</b>	/Rebecca B. Scarr/
<b>DATE SIGNED:</b>	10/08/2014
<b>Total Attachments: 3</b>	
source=32413_ExecAssign-Isis-RegLLC#page1.tif	
source=32413_ExecAssign-Isis-RegLLC#page2.tif	
source=32413_ExecAssign-Isis-RegLLC#page3.tif	

## ASSIGNMENT

**WHEREAS**, Isis Pharmaceuticals, Inc. a Delaware corporation having its principal office at 1896 Rutherford Road, Carlsbad, California 92008 (hereinafter referred to as the "Assignor") is the assignee of record of the inventions listed in "Table A"; and

**WHEREAS**, Regulus Therapeutics, LLC, a Delaware limited liability corporation having its principal office at 1896 Rutherford Road, Carlsbad, California 92008 (hereinafter referred to as the "Assignee") desires to acquire the entire interest in the same;

**NOW, THEREFORE**, for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor, hereby does assign and transfer unto Assignee, the entire right, title and interest in and to the patents and the applications listed in "Table A" throughout the world, including, without limitation, any letters patent which may issue thereon, and any subsequent application claiming priority to the above-identified application under reissue, reexamination, division, continuation-in-part, extension or continuation thereof and all rights of priority under international conventions arising from said applications; the same for its legal representatives and assigns, as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made;

**AND**, Assignor hereby binds itself, legal representatives, employees, successors and assigns to properly execute, without further consideration other than in reimbursement of directly related, reasonable expenses, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to perfect title in the patents and applications and carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and generally do everything possible to aid Assignee, its legal representatives, successors and assigns, to obtain proper protection for the inventions in all countries throughout the world, including to communicate to Assignee, its representatives or agents, any facts relating to the inventions, the patents or applications, including evidence for purposes of interference, opposition; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective.

Assignor hereby authorizes and requests the issuing authority to record this assignment of the patents and applications in "Table A" and to issue any and all patents on said applications to Assignee, as assignee of the entire interest in such patents.

IN WITNESS WHEREOF, I have executed this Assignment on the date shown below on behalf of Isis Pharmaceuticals, Inc..

  
Name: B. Lynne Parshall

11/8/07  
DATE

Title: Chief Financial Officer and Executive Vice President

Address: Isis Pharmaceuticals, Inc.  
1896 Rutherford Road  
Carlsbad, California 92008

On this 8<sup>th</sup> day of November, 2007, before me, the undersigned, a Notary Public for the state, personally appeared B. Lynne Parshall, personally known to me/proved to me on the basis of satisfactory evidence to be the person who subscribed the foregoing Assignment and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the Assignment the person, or the entity on behalf of which the person acted, executed the Assignment.



[SEAL]

WITNESS my hand and official seal.


  
Signature of Notary

Table A

Docket Number	Country	Serial Number	Filing Date	Title
CORE0016CA	Canada	2,533,701	7/30/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016EP	European Patent Convention	4780181.6	7/30/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016IL	Israel	173364	7/30/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US	United States	10/909,125	7/30/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US.L	United States	60/492,056	7/31/2003	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US.L2	United States	60/516,303	10/31/2003	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US.L3	United States	60/531,596	12/19/2003	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US.L4	United States	60/562,417	4/14/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0016US.P1	United States	11/329,992	1/10/2006	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR THE USE IN MODULATION OF PRI-MIRNAS
CORE0016WO	Patent Cooperation Treaty	PCT/US2004/025300	7/30/2004	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
CORE0060US	United States	11/513,102	8/29/2006	METHODS FOR USE IN MODULATING MIR-122a
CORE0060US.L	United States	60/712,211	8/29/2005	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATING MIR-122
CORE0060US.L2	United States	60/731,377	10/28/2005	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATING MIR-122
CORE0060US.L3	United States	60/771,592	2/7/2006	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATING MIR-122
CORE0060WO	Patent Cooperation Treaty	PCT/US2006/033866	8/29/2006	METHODS FOR USE IN MODULATING MIR-122a
CORE0060WO2	Patent Cooperation Treaty	PCT/US2006/034032	8/29/2006	ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY